Cohorte Nationale VIH-2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1185 participants

Study Classification

OBSERVATIONAL

Study Start Date

1994-01-01

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The HIV2 study is an open cohort of prospective, multicentric, national observation. The main objective is to study HIV-2 infection in adult patients followed in France.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The secondary objectives are :

* Describe the epidemiological and clinical characteristics of participants infected with HIV-2, and the immuno-virological characteristics of the infection.
* To study the clinical and immunological progression of HIV-2 infection and the prognostic factors of this evolution.
* Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.
* Allow an evaluation of the care practices of participants followed in French hospitals
* Provide a bank of clinical-biological data and samples allowing the performance of virological and / or immunological studies on HIV-2 infection.

The follow-up of the participants is different according to the therapeutic status of the participants, naive of antiretroviral treatment or already treated with antiretrovirals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-2 Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

virus HIV cohort

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antiretroviral

Study the response to antiretroviral treatment (clinical, immuno-virological) and contribute to the identification of the antiretroviral strategies and combinations most suited to the particularities of the infection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-2 infection only, diagnosed by ELISA, confirmed by Western-Blot test,
* Follow-up in consultation or hospitalization in one of the investigating centers,
* Age greater than or equal to 18 years,
* Prolonged follow-up possible, residence in France planned for at least one year,
* Consent to participate,
* Long-term medical care possible for the participant, or by medical aid (AME), or declaration of obtaining AME at the time of inclusion.

Exclusion Criteria

* HIV-1 infection
* Double HIV-1 + HIV-2 seropositivity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François Dabis, Pr, MD

Role: STUDY_DIRECTOR

ANRS, Emerging Infectious Diseases

Review the countries where the study has at least one active or historical site.

Identifier Type: -

Identifier Source: org_study_id

Cohorte Nationale VIH-2

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Interventions

Antiretroviral

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

ANRS, Emerging Infectious Diseases

Responsible Party

Principal Investigators

François Dabis, Pr, MD

Locations

Centre hospitalier Victor Dupouy

Avicenne

Hôpital Saint André

Service de Medecine Interne Hopital Antoine Beclere

Hôpital Louis Mourier

Hôpital Sud Francilien

Hôpital Henri Mondor

Service de Médecine interne - Centre Hospitalier Intercommunal

Hôpital Edouard Herriot

Hôpital de La Croix Rousse

Centre Hospitalier François Quesnay

Hôpital Gui de Chaudiac

Hôpital de l'Hotel Dieu

Hôpital Saint Louis

Hôpital Saint Antoine

Hôpital la Pitié Salpétrière

Service de Medecine Interne Hopital Cochin

Hôpital Bichat - Claude Bernard

Hôpital Tenon

Hôpital Hôtel Dieu

Hôpital Lariboisière

Hopital du Kremlin Bicêtre Service de médecine interne

Centre Hospitalier René Dubos

Hôpital Pontchaillou

Hôpital Delafontaine

CHI Poissy Saint Germain en Laye

Hôpital Bretonneau - Service des Maladies Infectieuses

Hôpital André Mignot

CHI Villeneuve Saint Georges

Countries

Central Contacts

Sophie Matheron, Pr, MD

Julie Longobardi

Facility Contacts

Philippe PG GENET, MD

Juliette JG GERBE

Olivier OB BOUCHAUD, PhD

MOHAMED KASSIM MKY YOUSSOUF, MD

Philippe Morlat, Pr

Francois Boue, MD

Emmanuel Mortier, MD

Jean-Daniel Lelievre, MD, PhD

Valérie GARRAIT, MD

Djamila MAKHLOUFI

Laurent COTTE

Ahmed JABBAR

Jacques Reynes

François RAFFI

Jean-Michel Molina, Pr

Marie Caroline Meyohas, Pr

Dominique Salmon, MD

Pialloux Gilles, Pr

Jean-Paul Viard, MD

Agathe Rami, Dr

Cécile Goujard, MD

Laurent BLUM

Cedric Arvieux, Dr

Marie-Aude KHUONG

Yves Welker, MD

Louis Bernard, PH

Alix Greder-Belan, MD